Bioo Scientific

Bioo Scientific, founded in 2003, is a rapidly expanding biotech company located in Austin, Texas. In 2006, the company was converted from LLC to C-corporation. Bioo Scientific has applied for patents to protect its RNAi agent delivery technology, drug technologies and test kit products. Additionally, Bioo Scientific has been awarded numerous SBIR grants that support our innovative product development activities from the National Institutes of Health (NIH), the United States Department of Agriculture (USDA) and the National Science Foundation (NSF). In addition, it has developed contracts with global research companies and governmental agencies, which enable Bioo Scientific to fund new technology development and create jobs.

Bioo Scientific’s focus areas include:

Food and Feed Safety Products

Bioo Scientific is a market leader in the food and feed safety testing industry. It develops, manufactures and markets a wide range of food and feed safety products for the detection of microbial and industrial contaminants, natural toxins, and veterinary drug residues.

Life Science Products

Bioo Scientific offers a wide range of products to facilitate life science and preclinical research. In addition to its innovative RNAi delivery solutions, their rapidly expanding product line includes gene-specific cytokine ELISAs, toxicology testing assays, tools for working with small RNAs, and kits which simplify DNA and RNA isolation and PCR and protein detection. Bioo Scientific also offers a comprehensive range of library preparation kits for Next Generation Sequencing.


Bioo Scientific has the experience and expertise to help you successfully complete preclinical drug development by designing, performing, and documenting safety tests that meet regulatory requirements. A few of the services that highly trained Bioo Scientific staff provide include in vivo RNAi/miRNA, immunohistochemistry, monoclonal antibody and protein and animal services at its USDA and OLAW approved animal facility.


This fall Bioo Scientific is scheduled to launch a new division, BiooTherapeutics, which will focus on leveraging the therapeutic potential of its proprietary technologies. Currently Bioo Scientific has seven novel drug candidates in its pipeline.